Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT

We thank all the patients who took part in the study, colleagues within the Sarah Cannon Research Institute UK site who cared for these patients, and Bartley O’Connor of Sqeeler Limited for the IT platform used during this pilot study. We also thank David Peters of Sequoia Medical Communications Ltd, who provided medical writing assistance funded by AstraZeneca, and colleagues within the AstraZeneca development team (most notably Åsa Strom, Stephanie Roberts, Christelle Gendrin, Paul Bonnet, Shamma Iqbal, and Shirley Spratt). This study was sponsored by AstraZeneca. The article processing charges and open access fee for this publication were funded by AstraZeneca. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.